Renewed interest in Alzheimer's vaccines due to breakthrough treatments
Breakthrough Alzheimer’s treatments have sparked renewed interest in vaccines to treat the disease. Clinical trials for at least seven Alzheimer’s vaccines are underway or completed, aiming to remove toxic proteins from the brain. Recent successes with antibody treatments have reignited hope for vaccines. Vaxxinity's UB-311 vaccine has shown promise in a Phase 2a trial, with 14% developing brain bleeding. The vaccines are seen as a potentially cheaper and more accessible option for the estimated 39 million people globally with Alzheimer’s.